Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gray matter

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Gray matter. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2013-000336-97 Sponsor Protocol Number: rhLAMAN-07 Start Date*: 2015-01-30
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis
    Medical condition: Alpha-Mannosidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10032658 Other specified disorders of carbohydrate transport and metabolism LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-012179-82 Sponsor Protocol Number: B0401005 Start Date*: 2010-01-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-020427-43 Sponsor Protocol Number: B0401011 Start Date*: 2010-10-13
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF 04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE ON STABLE DONEPEZIL THERAPY
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003816-20 Sponsor Protocol Number: MARYLU Start Date*: 2021-11-09
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: IMPACT OF STRUCTURAL AND MYELIN ABNORMALITIES ON COGNITIVE IMPAIRMENTS IN RECENT-ONSET SCHIZOPHRENIA – before and after lurasidone treatment
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003577-63 Sponsor Protocol Number: DYNAMICS_Study Start Date*: 2022-04-06
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsing-remitting multiple sclerosis: correlation with disease activity, cognition, fatigue, depression and quality o...
    Medical condition: Multiple sclerosis patients in relapse and remission form
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002858-36 Sponsor Protocol Number: FIM-DON-2017-01 Start Date*: 2018-09-19
    Sponsor Name:FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud
    Full Title: STUDY OF THE EFFECTIVENESS AND CEREBRAL REORGANIZATION AFTER TREATMENT COMBINED WITH DONEPEZILO, INTENSIVE REHABILITATION AND TRANSCRANEAL DIRECT CURRENT STIMULATION IN POSTSTROKE CHRONIC AFASIA
    Medical condition: Chronic poststroke aphasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002948 Aphasia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004833-25 Sponsor Protocol Number: UNLOCK Start Date*: 2017-03-29
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
    Full Title: Synchronous effect of anesthetics on fMRI, EEG and clinical responses. Development of a more precise system for monitoring anesthetic effect.
    Medical condition: General anaesthesia in healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021978-11 Sponsor Protocol Number: 101MS326 Start Date*: 2011-05-04
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis
    Medical condition: Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) FI (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) ES (Completed) PL (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000967-15 Sponsor Protocol Number: 221AD302 Start Date*: 2016-04-20
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease
    Medical condition: Early Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NL (Completed) ES (Temporarily Halted) BE (Completed) FR (Completed) PL (Completed) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004143-13 Sponsor Protocol Number: SHP-609-302 Start Date*: 2015-03-19
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome...
    Medical condition: Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    20.0 10010331 - Congenital, familial and genetic disorders 10056917 Hunter's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000966-72 Sponsor Protocol Number: 221AD301 Start Date*: 2015-09-10
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease
    Medical condition: Early Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) AT (Completed) FR (Completed) PT (Completed) ES (Temporarily Halted) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004404-18 Sponsor Protocol Number: ARIANNA Start Date*: 2021-12-15
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: The impact of aripiprazole long-acting on myelin and cognition in the onset of schizophrenia
    Medical condition: Onset of schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002181-38 Sponsor Protocol Number: WARCEF Start Date*: 2004-10-22
    Sponsor Name:NIH-National Institut of Health - NINDS-National Institut of Neurogical Disorders and Stroke
    Full Title: Warfarin versus Aspirin in Reduced Ejection Fraction.
    Medical condition: Patients with left ventricular disfunction with ejection fraction less or equal to 35%.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 19 08:06:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA